← All stocks

Cue Biopharma, Inc.

CUE Net buying
CIK 0001645460 #3995 in the set updated 17 Sep 2026
Bought (120 mo)
$5.98M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$5.68M
$0.00 on a plan · $3.73M straight out of an exercise
Sold at will
$1.95M
10 of 35 sales
Net
+$302.95K
+$4.03M against sales at will

By person

20 insiders · 79 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Fletcher Aaron G.L.
Director
$4.48M (6)
+$4.48M
1,113,867
$32.84M
+597.0%
Lin Shao-Lee
Chief Executive Officer
$1.61M (5) scheduled
−$1.61M
705,995
$20.81M
MARLETT CHRISTOPHER A
Director
$463.17K (10)
$1.43M (7)
−$963.51K
768,503
$22.66M
−23.8%
Suri Anish
PRESIDENT AND CSO
$19.78K (2)
$890.52K (6) scheduled
−$870.74K
135,638
$4.00M
+203.1%
Pienta Kenneth
Chief Medical Officer
$55.98K (2)
$509.66K (4) scheduled
−$453.68K
2,000
$58.96K
Kiener Peter A
Director
$392.28K (3) scheduled
−$392.28K
357
$10.52K
DIGIANDOMENICO ANTHONY
Director
$275.54K (5)
+$275.54K
57,000
$1.68M
Ray Sumita
Chief Legal Compliance Officer
$265.63K (3) scheduled
−$265.63K
118,545
$3.49M
+117.2%
Sandercock Colin
SVP, GENERAL COUNSEL
$132.66K (2)
$398.01K (3) scheduled
−$265.35K
17,125
$504.85K
+9,058%
PASSERI DANIEL R
CHIEF EXECUTIVE OFFICER
$187.89K (7)
+$187.89K
164,578
$4.85M
+311.4%
Meluzio Michael Vincent
VP, Prin. Accounting Officer
$169.32K (3) scheduled
−$169.32K
48,961
$1.44M
Gray Cameron
Director
$151.50K (2)
+$151.50K
687,049
$20.25M
+2.9%
Morich Frank
Director
$105.00K (1)
+$105.00K
28,000
$825.44K
Sarraf Pasha
Director
$99.75K (5)
+$99.75K
32,595
$960.90K
Millar Kerri-Ann
CHIEF FINANCIAL OFFICER
$8.48K (1)
$17.78K (1) scheduled
−$9.30K
14,311
$421.89K
Borie Dominique Christian
Chief Medical Officer
31,500
$928.62K
Ahlers James M
Chief Financial Officer
25,500
$751.74K
Garzone Pamela
Director
21,800
$642.66K
Camardo Daniel A.
Director
21,800
$642.66K
Meehan Viola Mong
Director
21,800
$642.66K

No percentages here. This company's share count has moved by a factor of 13.4 over the window, from 7,264,414 to 97,660,791 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 211
Amendments (4/A) skipped 6
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 25
Sales at will 10
Transactions with no price 0
Shares from compensation/vesting 3,484,440
Sales filed before the plan box existed 7
History held since 27 Dec 2017